Technology

Staying ahead in pre-clinical research, clinical applications or commercialization means planning from step one.

The problem is, no matrix for growing embryonic stem cells has enabled you to obtain stable, reliable, biologically relevant research results AND proceed with your findings to clinical applications.

Why?

  • It has been extremely difficult to obtain FDA/EMEA approval for using stem cells for regenerative medicine
  • Batches varied in structure, making your research results inconsistent and irreproducible
  • Undifferentiated cell growth can only be sustained for a very limited time
  • The production process involves non-human sources

Stem cells are difficult to grow. To keep them alive and expanding, they need to grow on a special supportive structure – a growth matrix. Basal laminae are the natural substrates for nearly all types of cells in vivo, and are therefore the natural matrices on which to grow organ cells on in vitro. Laminins are the most abundant components of basal laminae.

Of the matrices available on the market today, studies show that laminin-based ones provide the best support. The problem is that all of these matrices use laminin-111, which does not optimally support different cell types.

At BioLamina, we understand that one size does not fit all. After 30 years as leaders in the basal lamina field, we know that different cell types require different substrate solutions.

The solution

BioLamina has the ONLY human substrate solutions on the market today that enable you to obtain stable research results AND proceed to clinical trials. Our research shows that biologically-specific recombinant laminins are the missing link to commercializing stem cell research. BioLamina has patented unique technology for the manufacture and use of three human recombinant laminins – 511, 411 and 332.

This puts us way ahead of the competition. Why? Because BioLamina’s human recombinant laminins and methods are UNIQUE. We provide the ONLY substrates and methods available on the market today that enable REPRODUCIBLE SCIENTIFIC RESULTS for a range of cell types.

The ONLY system that is feasible for GMP production – thus facilitating entry to clinical trials. What’s more, our system is also the ONLY one on the market that has the ability to promote indefinite self-renewal of pluripotent embryonic and adult stem cells. Not only do you get all this, but our substrates are also ideal for a wide range of somatic cell types. Click on our product pages to learn more.

To recap, BioLamina human recombinant laminins:

  • Meet FDA/EMEA regulatory guidelines
  • Have a defined composition
  • Sustain pluripotent growth for up to several months
  • Are biologically specific for different cell types
  • Are produced entirely from animal-free sources